 |
Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Jan 2, 2012
|
9.6 KB |
|
| |
TARRYTOWN, N.Y., Jan. 2, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. Eastern Time to provide an update on the status of the ongoing patent litigation with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY).
...
|
|
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
Dec 5, 2011
|
20.4 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, Dec. 5, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in an integrated analysis of two parallel Phase 3 studies (VIEW 1 and VIEW 2) in patients with the neovascular form of age-related macular degeneration (wet AMD), patients treated with EYLEA™ (aflib...
|
|
Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Dec 1, 2011
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Dec. 1, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a time change for the Company's presentation at the 2011 Deutsche Bank BioFEST scheduled for Monday, December 5, 2011. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, ww...
|
|
Regeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China
Nov 28, 2011
|
18.7 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, Nov. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA™ (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.
...
|
|
Regeneron Announces Upcoming Investor Conference Presentations
Nov 23, 2011
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Nov. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
23rd Annual Piper Jaffray Healthcare Conference at 1:00 p.m. Eastern Time on Tuesday, November 29, 2011
2011 Deutsche Bank BioFEST at 9:00 a.m. Eastern Time on Mond...
|
|
Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Nov 22, 2011
|
19.1 KB |
|
| |
TARRYTOWN, N.Y., Nov. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating ur...
|
|
Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
Nov 21, 2011
|
12.6 KB |
|
| |
TARRYTOWN, N.Y., Nov. 21, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has elected Marc Tessier-Lavigne, Ph.D. to fill a new seat on its expanded Board of Directors. Dr. Tessier-Lavigne is President of The Rockefeller University in New York City, one of the world's preeminent medical research institut...
|
|
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration: CORRECTED
Nov 18, 2011
|
22.5 KB |
|
| |
In the news release, Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration, issued 18-Nov-2011 by Regeneron Pharmaceuticals, Inc. over PR Newswire, the third paragraph, second sentence, should read "EYLEA offers the potential of achieving the efficacy we've come to expect ...
|
|
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Nov 10, 2011
|
21.2 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Nov. 10, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553.
REGN727/SAR23...
|
|
Regeneron Announces Presentation at the 2011 Credit Suisse Annual Healthcare Conference
Nov 7, 2011
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Nov. 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2011 Credit Suisse Annual Healthcare Conference on Wednesday, November 9, 2011. The presentation is scheduled for 9:30 a.m. Mountain Time (11:30 a.m. Eastern Time). The session may be accessed through the Company's web...
|
|
Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
Oct 27, 2011
|
14.6 KB |
|
| |
TARRYTOWN, N.Y., Oct. 27, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab (REGN88/SAR153191) in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming America...
|
|
Regeneron Reports Third Quarter 2011 Financial and Operating Results
Oct 27, 2011
|
26.7 KB |
|
| |
TARRYTOWN, N.Y., Oct. 27, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2011 and provided an update on development programs and upcoming milestones.
Clinical Programs Update
EYLEA™ (aflibercept injection) — Ophthalmologic Diseases
EYLEA™, ...
|
|
Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
Oct 18, 2011
|
14.3 KB |
|
| |
TARRYTOWN, N.Y., Oct. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced the pricing of its offering of $400 million aggregate principal amount of 1.875% convertible senior notes due October 1, 2016. The notes will be offered by the initial purchaser only to qualified institutional buyers pursuant to ...
|
|
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Oct 17, 2011
|
13.8 KB |
|
| |
TARRYTOWN, N.Y., Oct. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced that it intends to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2016 in a private placement. The notes will be offered by the initial purchaser only to qua...
|
|
Regeneron Announces ZALTRAP® Clinical Presentation at European Multidisciplinary Cancer Congress
Sep 23, 2011
|
13.4 KB |
|
| |
TARRYTOWN, N.Y., Sept. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.
The data will be presented as a late b...
|
|
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Sep 15, 2011
|
11.0 KB |
|
| |
TARRYTOWN, N.Y., Sept. 15, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #2 employer in the global biopharmaceutical industry in its annual survey of Top Employers.
"It is extremely satisfying for Regeneron to be recognized by Science as one of the best plac...
|
|
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Sep 6, 2011
|
10.1 KB |
|
| |
TARRYTOWN, N.Y., Sept. 6, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Joseph J. LaRosa has been appointed Senior Vice President, General Counsel and Secretary. Mr. LaRosa will be responsible for overseeing all of the Company's legal affairs, including general corporate legal matters, intellectual proper...
|
|
Regeneron Announces September 2011 Investor Conference Presentations
Aug 31, 2011
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Aug. 31, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Citi's 6th Annual Biotech Day panel discussion on the topic "Eye Can See Clearly Now the Rain is Gone: New Drugs for Wet AMD" at 9:00 a.m. Eastern Time on Wednesday, September ...
|
|
Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
Aug 17, 2011
|
11.5 KB |
|
| |
TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA™ (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Bosto...
|
|
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Aug 16, 2011
|
91.5 KB |
|
| |
TARRYTOWN, N.Y., Aug. 16, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascula...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds